<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656069</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-301</org_study_id>
    <nct_id>NCT02656069</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics</brief_title>
  <official_title>G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen
      (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for
      hypoglycemia rescue of adult patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded, randomized, Phase 3 comparative efficacy and safety study in adults with
      type 1 diabetes. Patients will complete screening procedures up to 60 days before
      randomization to determine eligibility before enrollment to the treatment phase.

      The procedure for evaluating the efficacy of the G-Pen (glucagon injection) consists of
      inducing hypoglycemia by intravenous administration of regular insulin diluted in normal
      saline. Each participant will undergo two episodes of insulin-induced hypoglycemia, and in
      random order will receive 1 mg G-Pen (glucagon injection) during one episode and 1 mg Lilly
      Glucagon during the other episode. There will be wash out period of 7-28 days between
      treatment visits.

      Blood glucose levels will be monitored post-dosing, with a return of plasma glucose to a
      concentration &gt; 70 mg/dL within 30 minutes signifying successful hypoglycemia rescue. As a
      confirmation of efficacy, subjects will complete a questionnaire concerning changes in
      symptoms of hypoglycemia following treatment with glucagon.

      Subjects will return for a follow-up safety visit 3-14 days following administration of the
      final dose of glucagon.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Actual">September 25, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemia Rescue: Intent-to-Treat Population</measure>
    <time_frame>At 30 minutes following administration of study drug</time_frame>
    <description>Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemia Rescue: Per Protocol Population</measure>
    <time_frame>At 30 minutes following administration of study drug</time_frame>
    <description>Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemia Rescue: Alternate Glucose Response Definition</measure>
    <time_frame>At 30 minutes following administration of study drug</time_frame>
    <description>Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or an increase in from baseline in plasma glucose concentration of at least 20 mg/dL within 30 minutes after administration of glucagon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Area Under the Curve (AUC)</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, and 90 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of plasma glucose AUC from baseline to 90 minutes following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Maximum Concentration (Cmax)</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of plasma glucose Cmax from baseline to 4 hours following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Time to Maximum Concentration (Tmax)</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of plasma glucose Tmax from baseline to 4 hours following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Time to Concentration &gt; 70 mg/dL</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of time to achieve a plasma glucose concentration &gt; 70 mg/dL following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Hypoglycemia Symptoms</measure>
    <time_frame>At 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 minutes following administration of glucagon</time_frame>
    <description>Time to resolution of mean autonomic, mean neuroglycopenic and mean total hypoglycemia symptom scores from baseline through 90 minutes following administration of glucagon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Hypoglycemia</measure>
    <time_frame>At 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 minutes following administration of glucagon</time_frame>
    <description>Time to resolution of the overall sensation of hypoglycemia following administration of glucagon</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>G-Pen first, then Lilly Glucagon</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly Glucagon first, then G-Pen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen (glucagon injection)</intervention_name>
    <description>1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
    <arm_group_label>G-Pen first, then Lilly Glucagon</arm_group_label>
    <arm_group_label>Lilly Glucagon first, then G-Pen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lilly Glucagon (glucagon injection [rDNA origin])</intervention_name>
    <description>1 mg of Lilly glucagon reconstituted from lyophilized powder</description>
    <arm_group_label>G-Pen first, then Lilly Glucagon</arm_group_label>
    <arm_group_label>Lilly Glucagon first, then G-Pen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with type 1 diabetes mellitus for at least 24 months

          -  usage of daily insulin treatment

          -  random serum C-peptide concentration &lt; 0.5 ng/mL

        Exclusion Criteria:

          -  pregnant or nursing

          -  HbA1c &gt;9.0%

          -  renal insufficiency

          -  hepatic synthetic insufficiency

          -  aspartate or alanine aminotransferase &gt; 3 times the upper limit of normal

          -  hematocrit less than or equal to 30%

          -  use of &gt; 2.0 U/kg total insulin dose per day

          -  inadequate bilateral venous access in both arms

          -  congestive heart failure, New York Heart Association class II, III or IV

          -  active malignancy within 5 years, except basal cell or squamous cell skin cancers

          -  history of breast cancer or malignant melanoma

          -  major surgical operation within 30 days

          -  current seizure disorder.

          -  current bleeding disorder, treatment with warfarin, or platelet count below 50,000

          -  history of pheochromocytoma or disorder with increased risk of pheochromocytoma

          -  history of insulinoma

          -  history of glycogen storage disease.

          -  positive for HIV, hepatitis C virus or active hepatitis B virus infection

          -  whole blood donation of 1 pint (500 mL) within 8 weeks

          -  active substance or alcohol abuse

          -  administration of glucagon within 28 days

          -  participation in other studies involving an investigational drug or device within 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Endocrinology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <results_first_submitted>August 31, 2018</results_first_submitted>
  <results_first_submitted_qc>August 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2018</results_first_posted>
  <last_update_submitted>September 29, 2018</last_update_submitted>
  <last_update_submitted_qc>September 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02656069/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period began 15 March 2017 and ran through 30 June 2017. Subjects were screened for study eligibility at one of the 7 clinical sites up to 60 days prior to randomization.</recruitment_details>
      <pre_assignment_details>A total of 6 screened and eligible subjects were not randomized to one of the treatment sequences due to closing of the enrollment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-Pen First, Then Lilly Glucagon</title>
          <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
G-Pen™ (glucagon injection): 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Lilly Glucagon (glucagon injection [rDNA origin]): 1 mg of Lilly glucagon reconstituted from lyophilized powder</description>
        </group>
        <group group_id="P2">
          <title>Lilly Glucagon First, Then G-Pen</title>
          <description>A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen™ (glucagon injection)
Lilly Glucagon (glucagon injection [rDNA origin]): 1 mg of Lilly glucagon reconstituted from lyophilized powder
G-Pen™ (glucagon injection): 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible, randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>G-Pen First, Then Lilly Glucagon</title>
          <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
G-Pen™ (glucagon injection): 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Lilly Glucagon (glucagon injection [rDNA origin]): 1 mg of Lilly glucagon reconstituted from lyophilized powder</description>
        </group>
        <group group_id="B2">
          <title>Lilly Glucagon First, Then G-Pen</title>
          <description>A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen™ (glucagon injection)
Lilly Glucagon (glucagon injection [rDNA origin]): 1 mg of Lilly glucagon reconstituted from lyophilized powder
G-Pen™ (glucagon injection): 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" spread="15.55"/>
                    <measurement group_id="B2" value="45.5" spread="14.87"/>
                    <measurement group_id="B3" value="43.6" spread="15.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Non-Hispanic White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <title>Canada</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>United Staates</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hypoglycemia Rescue: Intent-to-Treat Population</title>
        <description>Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
        <time_frame>At 30 minutes following administration of study drug</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Rescue: Intent-to-Treat Population</title>
          <description>Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypoglycemia Rescue: Per Protocol Population</title>
        <description>Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
        <time_frame>At 30 minutes following administration of study drug</time_frame>
        <population>All randomized, treated subjects without a major protocol violation</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Rescue: Per Protocol Population</title>
          <description>Number of subjects with an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
          <population>All randomized, treated subjects without a major protocol violation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypoglycemia Rescue: Alternate Glucose Response Definition</title>
        <description>Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or an increase in from baseline in plasma glucose concentration of at least 20 mg/dL within 30 minutes after administration of glucagon</description>
        <time_frame>At 30 minutes following administration of study drug</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Rescue: Alternate Glucose Response Definition</title>
          <description>Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or an increase in from baseline in plasma glucose concentration of at least 20 mg/dL within 30 minutes after administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Area Under the Curve (AUC)</title>
        <description>Pharmacodynamic endpoint of plasma glucose AUC from baseline to 90 minutes following administration of glucagon</description>
        <time_frame>At -5, 0, 10, 20, 30, 45, 60, and 90 minutes following administration of glucagon</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Area Under the Curve (AUC)</title>
          <description>Pharmacodynamic endpoint of plasma glucose AUC from baseline to 90 minutes following administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11651.4" spread="2406.9"/>
                    <measurement group_id="O2" value="12260.4" spread="2134.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Maximum Concentration (Cmax)</title>
        <description>Pharmacodynamic endpoint of plasma glucose Cmax from baseline to 4 hours following administration of glucagon</description>
        <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Maximum Concentration (Cmax)</title>
          <description>Pharmacodynamic endpoint of plasma glucose Cmax from baseline to 4 hours following administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.7" spread="41.8"/>
                    <measurement group_id="O2" value="193.5" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Time to Maximum Concentration (Tmax)</title>
        <description>Pharmacodynamic endpoint of plasma glucose Tmax from baseline to 4 hours following administration of glucagon</description>
        <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Time to Maximum Concentration (Tmax)</title>
          <description>Pharmacodynamic endpoint of plasma glucose Tmax from baseline to 4 hours following administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.3" spread="33.5"/>
                    <measurement group_id="O2" value="100.4" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Time to Concentration &gt; 70 mg/dL</title>
        <description>Pharmacodynamic endpoint of time to achieve a plasma glucose concentration &gt; 70 mg/dL following administration of glucagon</description>
        <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Time to Concentration &gt; 70 mg/dL</title>
          <description>Pharmacodynamic endpoint of time to achieve a plasma glucose concentration &gt; 70 mg/dL following administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="8.5"/>
                    <measurement group_id="O2" value="14.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Hypoglycemia Symptoms</title>
        <description>Time to resolution of mean autonomic, mean neuroglycopenic and mean total hypoglycemia symptom scores from baseline through 90 minutes following administration of glucagon.</description>
        <time_frame>At 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 minutes following administration of glucagon</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Hypoglycemia Symptoms</title>
          <description>Time to resolution of mean autonomic, mean neuroglycopenic and mean total hypoglycemia symptom scores from baseline through 90 minutes following administration of glucagon.</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Autonomic Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="11.5"/>
                    <measurement group_id="O2" value="14.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuroglycopenic Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="10.2"/>
                    <measurement group_id="O2" value="14.3" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="11.7"/>
                    <measurement group_id="O2" value="17.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Hypoglycemia</title>
        <description>Time to resolution of the overall sensation of hypoglycemia following administration of glucagon</description>
        <time_frame>At 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 minutes following administration of glucagon</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Hypoglycemia</title>
          <description>Time to resolution of the overall sensation of hypoglycemia following administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="10.7"/>
                    <measurement group_id="O2" value="15.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Hypoglycemia Rescue: Glucose or Symptomatic Response Definition</title>
        <description>Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or resolution of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after administration of glucagon</description>
        <time_frame>At 30 minutes following administration of study drug</time_frame>
        <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Rescue: Glucose or Symptomatic Response Definition</title>
          <description>Number of subjects with either an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL or resolution of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after administration of glucagon</description>
          <population>Modified intent-to-treat population of all randomized subjects analyzed by actual treatment received</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the first intervention, treatment emergent adverse events were defined as adverse events occurring at any time after receipt of the first intervention and prior to receipt of the second intervention, 7-28 days later. For the second intervention, treatment emergent adverse events were defined as adverse events occurring at any time after receipt of the second intervention and prior to completion of the follow-up evaluation visit occurring 3-14 days later.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-Pen</title>
          <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)</description>
        </group>
        <group group_id="E2">
          <title>Lilly Glucagon</title>
          <description>A single 1 mg subcutaneous (SC) injection of Lilly Glucagon</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperinsulinemic hypoglycemia</sub_title>
                <description>The evening after receiving Lilly Glucagon 1 mg, a subject had severe hypoglycemia at home requiring 3rd party assistance. An emergency medical technician administered saline. The subject recovered with no sequelae and completed the study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin J. Cummins, VP, Clinical Development</name_or_title>
      <organization>Xeris Pharamaceuticals, Inc.</organization>
      <phone>806-282-2120</phone>
      <email>mcummins@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

